Inclisiran is listed as a possible option for statin-intolerant patients.

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Inclisiran is listed as a possible option for statin-intolerant patients.

In the management of high cholesterol, when patients can’t tolerate statins, clinicians look for non-statin therapies to lower LDL-C. Inclisiran fits here because it’s a PCSK9 pathway–targeting treatment delivered as a small interfering RNA. By silencing PCSK9 production in the liver, more LDL receptors stay active, so the liver clears more LDL from the blood, typically reducing LDL-C by about half. It’s approved for adults with primary hyperlipidemia or mixed dyslipidemia and is positioned as an option for statin-intolerant patients due to its mechanism and relatively convenient dosing (a few initial injections, then every six months). That’s why the statement is correct: inclisiran is listed as a possible option for statin-intolerant patients. It’s not a first-line statin substitute, and its use isn’t limited to diabetes.

In the management of high cholesterol, when patients can’t tolerate statins, clinicians look for non-statin therapies to lower LDL-C. Inclisiran fits here because it’s a PCSK9 pathway–targeting treatment delivered as a small interfering RNA. By silencing PCSK9 production in the liver, more LDL receptors stay active, so the liver clears more LDL from the blood, typically reducing LDL-C by about half. It’s approved for adults with primary hyperlipidemia or mixed dyslipidemia and is positioned as an option for statin-intolerant patients due to its mechanism and relatively convenient dosing (a few initial injections, then every six months). That’s why the statement is correct: inclisiran is listed as a possible option for statin-intolerant patients. It’s not a first-line statin substitute, and its use isn’t limited to diabetes.

More practice questions